相关临床试验
77
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1321
进行中（未招募）
3
3.9%
已完成
36
46.8%
尚未招募
3
3.9%
招募中
17
22.1%
暂停
2
2.6%
终止
2
2.6%
Unknown
14
18.2%
暂无批准数据
- A first-of-its-kind meta-analysis of 574 men with oligometastatic prostate cancer demonstrates that metastasis-directed therapy significantly improves progression-free survival by 7.6 months compared to standard care alone. - The WOLVERINE study, published in The Lancet Oncology, provides the highest level of evidence to date supporting metastasis-directed therapy, primarily stereotactic body radiation therapy, for treating limited metastatic disease. - Patients receiving metastasis-directed therapy showed consistent benefits across multiple endpoints including radiographic progression-free survival and castration resistance-free survival, with no additional safety risks observed.
- Researchers identified baseline serum metabolic signatures that predict clinical outcomes in 71 metastatic melanoma patients treated with immune checkpoint inhibitors, achieving concordance indices of 0.72-0.74 for the full cohort and 0.81-0.9 for first-line patients. - High glucose levels emerged as a consistent negative prognostic factor for both overall survival and progression-free survival, while glutamine and HDL-related metabolites showed protective effects. - The metabolomic risk models successfully stratified patients into high-risk and low-risk groups with statistically significant differences in survival outcomes, potentially enabling personalized treatment approaches.
